Current Melanoma News and Events | Page 25

Current Melanoma News and Events, Melanoma News Articles.
Sort By: Most Relevant | Most Viewed
Page 25 of 25 | 1000 Results
Removal of tumor-associated immune cell protein decreases tumor progression
In this issue of the Journal of Clinical Investigation, Shelley Earp and colleagues at the University of North Carolina a Chapel Hill demonstrate that removal of the protein MerTK from immune cells decreased tumor growth in mouse models of breast cancer, melanoma, and colon cancer. (2013-07-08)

How cancer spreads: Metastatic tumor a hybrid of cancer cell and white blood cell
Yale Cancer Center scientists, together with colleagues at the Denver Police Crime Lab and the University of Colorado, have found evidence that a human metastatic tumor can arise when a leukocyte (white blood cell) and a cancer cell fuse to form a genetic hybrid. (2013-07-02)

Surgeons report melanoma recurs after 10 years in more than 6 percent of patients
Recurrence of melanoma skin cancer 10 or more years after initial treatment is more common than previously thought, occurring in more than one in 20 patients. However, according to a new study, these patients tend to live longer after their cancer returns than patients whose melanoma recurs in the first three years. The study results appear in the July issue of the Journal of the American College of Surgeons. (2013-06-27)

New screening approach identifies small proteins unique to melanoma cells, Moffitt researcher says
Jamie K. Teer, Ph.D., assistant member of the Cancer Biology and Evolution Program at Moffitt Cancer Center, and colleagues have developed a new streamlined method to rapidly identify the genetic changes in small protein fragments unique to melanoma cancer cells. These fragments can be used as targets for tumor-infiltrating lymphocytes that have been shown to reduce cancerous lesions. (2013-06-25)

Modified immune cells seek and destroy melanoma
In this issue of the Journal of Clinical Investigation, researchers led by Scott Pruitt at Duke University and Merck Research Laboratories report on a human clinical trial in which modified dendritic cells, a component of the immune system, were tested in patients with melanoma. (2013-06-24)

Herding cancer cells to their death
Publishing their findings in today's online issue of Cancer Cell, an international team of scientists led jointly by Professors Colin Goding from the Ludwig Institute for Cancer Research who is based at the University of Oxford and José Neptuno Rodriguez-López from the University of Murcia describe a therapeutic strategy that manipulates a mechanism driving cellular heterogeneity to treat advanced melanoma. (2013-06-20)

Monell-led research identifies scent of melanoma
Monell researchers identified odorants from human skin cells that can be used to identify melanoma, the deadliest form of skin cancer. In addition, a nanotechnology-based sensor could utilize the odor profiles to reliably differentiate melanoma cells from normal skin cells. Non-invasive odor analysis may be a valuable technique in the detection and early diagnosis of human melanoma. (2013-06-13)

Diabetes drug points the way to overcoming drug resistance in melanoma
Despite the success of melanoma-targeting drugs, tumors inevitably become drug resistant and return, more aggressive than before. In the current issue of the journal Cancer Cell, however, researchers at The Wistar Institute describe how they increase the effectiveness of anti-melanoma drugs by combining anticancer therapies with diabetes drugs. Their studies, conducted in cell and animal models of melanoma, demonstrate that the combined therapy could destroy a subset of drug-resistant cells within a tumor. (2013-06-11)

First dual-action compound kills cancer cells, stops them from spreading
Scientists are reporting development and successful lab tests on the first potential drug to pack a lethal one-two punch against melanoma skin cancer cells. Hit number one destroys cells in the main tumor, and the second hit blocks the spread of the cancer to other sites in the body, according to their report in the journal ACS Chemical Biology. (2013-06-05)

Combination of drugs produces dramatic tumor responses in advanced melanoma patients
The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to new research from Memorial Sloan-Kettering Cancer Center. (2013-06-02)

New cancer drug shows promise for treating advanced melanoma
Results from the first clinical trial of lambrolizumab in patients with advanced melanoma shows significant anti-tumor activity with very manageable side effects in patients with advanced melanoma, the deadliest form of skin cancer. (2013-06-02)

New drug improves progression-free survival, shrinks tumors in rare cancer for first time
The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of the American Society of Clinical Oncology. (2013-06-01)

Mainz University obtains new CRC 'Nanodimensional polymer therapeutics for tumor therapy'
The German Research Foundation has established a new Collaborative Research Center on (2013-05-31)

Study of young Israelis emphasizes need for avoidance of sun exposure
A new study conducted using extensive medical records of over one million Israeli adolescents before military service shows clearly how exposure to the Israeli sun of young, light-skinned children increases substantially the risk of cutaneous melanoma (a serious form of skin cancer). (2013-05-20)

Mayo Clinic: Inflammatory bowel disease raises risk of melanoma
Patients with inflammatory bowel disease are at higher risk of melanoma, a form of skin cancer, report researchers at Mayo Clinic. (2013-05-20)

Discovery of gene mutation causing Sturge-Weber syndrome, port-wine stain birthmarks offers new hope
In new findings published in the New England Journal of Medicine (Epub ahead of print), researchers from the Kennedy Krieger Institute reveal the discovery of the cause -- a genetic mutation that occurs before birth -- of Sturge-Weber syndrome (SWS) and port-wine stain birthmarks. SWS is a rare disorder affecting approximately one in 20,000 births, while port-wine birthmarks are more common, affecting approximately one million individuals in the United States. (2013-05-08)

Promising strategies to reduce use of indoor tanning devices and prevent skin cancer
Preventing skin cancer by reducing use of indoor tanning devices requires a coordinated approach at the national, state, and local levels suggests a pair of papers by CDC authors in a special theme issue of the American Journal of Preventive Medicine. Evidence has shown that use of indoor tanning devices increases the risk of developing skin cancer, including melanoma, and these papers discuss approaches that could help reduce use of indoor tanning devices and prevent future incidence of skin cancers. (2013-05-07)

New class of drug targets skin cancer
A new class of drug targeting skin cancer's genetic material has been successfully tested in humans for the first time, opening the way to new treatments for a range of conditions from skin cancers to eye diseases. (2013-05-06)

Food dye could provide 'blueprint' for treatment of Panx1-related diseases
The food dye Brilliant Blue FCF could be a useful tool in the development of treatments for a variety of conditions involving the membrane channel protein Pannexin 1, according to a study in the Journal of General. (2013-04-29)

Surgery for nonfatal skin cancers might not be best for elderly patients
Surgery is often recommended for skin cancers, but older, sicker patients can endure complications as a result and may not live long enough to benefit from the treatment. (2013-04-29)

Reviving a foe of cancer
p53 is a vitally important tumor suppressor whose function is disrupted in one way or another in various cancer types. In the recent issue of Cancer Cell, a research team, led by Xin Lu, Ph.D., Ludwig director and member at the University of Oxford, describes how p53 is silenced in advanced melanomas by a protein named iASPP, and applies that information to restore p53 function in such cells. (2013-04-25)

University of Houston engineering professor awarded grant to study melanoma treatment
A University of Houston engineering professor has won a grant from the Melanoma Research Alliance to help develop one of the most promising therapies for patients with the disease. (2013-04-25)

Skin cancer linked to future risk of other cancers
White people who have types of skin cancer other than melanoma (non-melanoma skin cancer) may be at increased risk of having other forms of cancer in the future, according to a study by US researchers published in this week's PLOS Medicine. (2013-04-23)

Virus kills melanoma in animal model, spares normal cells
Researchers from Yale University School of Medicine have demonstrated that vesicular stomatitis virus is highly competent at finding, infecting, and killing human melanoma cells, both in vitro and in animal models, while having little propensity to infect non-cancerous cells. (2013-04-23)

Researchers observe an increased risk of cancer in people with history of non-melanoma skin cancer
Researchers found that people with a history of non-melanoma skin cancer had a modestly increased risk of getting cancer in the future, specifically breast and lung cancer in women and melanoma in both men and women. (2013-04-23)

The Melanoma Research Alliance Foundation supports CNIO research
A consortium led by the Spanish National Cancer Research Centre's researcher María S. Soengas -- Programme Director of the Centre´s Molecular Pathology Programme and Leader of the CNIO Melanoma Group -- has been selected to receive funding from the Melanoma Research Alliance, the most important private international melanoma research foundation, in order to advance research in melanoma. (2013-04-23)

Researchers abuzz over caffeine as cancer-cell killer
University of Alberta research team uses caffeine and fruit flies to pinpoint genetic pathways that guide DNA repair in cancer cells. (2013-04-17)

CT and serum LDH shows promise as survival predictor for some metastatic melanoma patients
Combining CT imaging findings with baseline serum lactate dehydrogenase levels is showing promise as a way to predict survival in patients with metastatic melanoma being treated with anti-angiogenic therapy. (2013-04-17)

Transcription factors regulating blood oxygen linked to melanoma metastases
Researchers at the University of North Carolina have discovered that transcription factors regulating the levels of oxygen in the blood also play a role in the spread of the skin cancer melanoma. (2013-04-16)

When a KISS (1) goes bad
KISS 1 is a metastasis-suppressor gene which helps to prevent the spread of cancers, including melanoma, pancreatic and ovarian cancers to name a few. But new research from Western University's Schulich School of Medicine & Dentistry shows that kisspeptins -- peptide products of KISS1, actually make some breast cancers worse, with a higher tumor grade and metastatic potential. The research is published online in the journal Endocrinology. (2013-04-16)

Fish prone to melanoma get DNA decoded
Scientists at Washington University School of Medicine in St. Louis and elsewhere have decoded the genome of the platyfish, a cousin of the guppy and a popular choice for home aquariums. Among scientists, the fish are meticulously studied for their tendency to develop melanoma and for other attributes more common to mammals, like courting prospective mates and giving birth to live young. (2013-04-15)

Melanoma Research Alliance awards $9.6 million in research grants
The Melanoma Research Alliance, the largest private funder of melanoma research, today announced grant awards exceeding $9.6 million to 49 scientists at leading academic institutions around the world for investigating new treatments and cures for melanoma. Among the proposals is research to accelerate new therapeutic approaches for dealing with metastatic melanoma, often a fatal disease, including combination therapies, as well as a focus on a greater understanding of melanoma's initiation. (2013-04-15)

T cell biology pioneer Allison wins first AACR honor for cancer immunology
The discoverer of drug to treat T cells, not tumors, receives inaugural AACR-CRI Lloyd J. Old Award in Cancer Immunology. (2013-04-10)

Ludwig presents advancements in immunotherapy and epigenetics at the American Association for Cancer Research Annual Meeting
A dozen Ludwig scientists from around the world presented the latest advancements in basic and clinical cancer research at this week's American Association of Cancer Research Annual Meeting 2013. Progress in immunotherapy and epigenetics led the program with important diagnostic and treatment implications for emerging cancer therapy. (2013-04-10)

Naturally-occurring substance proves effective against deadly skin cancer in laboratory tests
For the first time, scientists have demonstrated the mechanism of action of gossypin, a naturally-occurring substance found in fruits and vegetables, as a treatment for melanoma, which causes the majority of deaths from skin cancer. (2013-04-10)

AACR news: New target plus new drug equals death of melanoma cells
Collaborative research presented by the University of Colorado Cancer Center, the University of North Carolina at Chapel Hill, Harvard Medical School and the University of Pittsburgh, at the American Association for Cancer Research Annual Conference, shows that the protein receptor Mer is overexpressed in melanoma and that the investigational drug UNC1062 blocks Mer survival signaling in these cells, killing them. (2013-04-09)

Shutting down DNA construction: How senescence halts growth of potential cancers
How does oncogene-induced senescence work? Imagine the cell as a construction site where work continues as long as bricks (nucleotides) are available. When an oncogene is damaged, it is like hiring excess workers and cancelling orders for bricks. When brick supplies run out, construction ends and the cell becomes senescent. (2013-04-04)

BU student receives 2013 Joanna M. Nicolay Melanoma Foundation scholarship award
The Joanna M. Nicolay Melanoma Foundation presented Elizabeth Shenk, a student in both the Boston University Biomedical Engineering Department and the Boston University School of Medicine Pharmacology Training Program with one of 10, nationally competitive, 2013 (2013-04-02)

UCLA, Caltech research on immune-cell therapy could strengthen promising melanoma treatment
UCLA and Caltech scientists have used newly developed nanotechnology chips (multidimensional and multiplexed immune monitoring assays) to successfully monitor T cells genetically engineered to attack melanoma. They have discovered that the T cells change over time when returned to patients. These results will help improve engineered immunotherapy for melanoma and the assays will help understand a spectrum of other cellular immunotherapies in the future. (2013-03-21)

Functional characteristics of antitumor T cells change w increasing time after therapeutic transfer
Beneficial effect of genetically engineered antitumor T cells was transient. Functionality of T cells changed over time. Strategies are needed to sustain antitumor functionality. (2013-03-21)

Page 25 of 25 | 1000 Results
   First   Previous   Next      Last is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to